Lexaria Bioscience Warrant
LEXXW
LEXXW was delisted on the 13th of January, 2026.
3 hedge funds and large institutions have $39.3K invested in Lexaria Bioscience Warrant in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
38% less capital invested
Capital invested by funds: $63.9K → $39.3K (-$24.6K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$17.8K |
| 2 |
CS
Clear Street
New York
|
-$78 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
1
Heights Capital Management
San Francisco,
California
| $35.1K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $4.2K | -$17.8K | -22,886 | -82% |
|
|
CS
3
Clear Street
New York
| $76 | -$78 | -100 | -50% |
|
LEXXW Hedge Fund Activity: Q4 2024 in Review
3 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q4 2024, worth a combined $39.3K — down 38% from $63.9K a quarter earlier.
Fund positioning in LEXXW was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was UBS Group, cutting an estimated $17.8K.
- 3 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $39.3K of Lexaria Bioscience Warrant stock for Q4 2024, down 38% quarter-over-quarter.
- 0 funds opened new Lexaria Bioscience Warrant positions in Q4 2024 and 0 closed out.
- The largest Lexaria Bioscience Warrant seller in Q4 2024 was UBS Group, an estimated $17.8K sold.
Based on aggregated 13F filings for Q4 2024.